This A5 Flyer provides ophthalmologists with an overview of the current landscape of biosimilars in retinal diseases, focusing on anti-VEGF therapies and aflibercept 2 mg biosimilars. It explores key clinical evidence, patient switching considerations, and biosimilar selection to support clinical practice, maintain patient outcomes, and promote healthcare cost savings

Leadtime:
Production: 2-4 working days
Delivery 3-6 working days

Stock: 
170GSM Satin